Sigyn Therapeutics (SIGY) Liabilities from Discontinued Operations (2017 - 2018)
Sigyn Therapeutics (SIGY) posted Liabilities from Discontinued Operations of 162978.0 for Q4 2018, down 67.32% sequentially from 498635.0 in Q4 2017, and down 67.32% YoY from 498635.0 in Q4 2017.
Sigyn Therapeutics (SIGY) Liabilities from Discontinued Operations (2017 - 2018) Analysis & Trends
Sigyn Therapeutics has reported Liabilities from Discontinued Operations for 2 years, with the latest figure at 162978.0 in Q4 2018.
- Quarterly Liabilities from Discontinued Operations fell 67.32% year-over-year to 162978.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was 162978.0 (down 67.32% YoY) and the FY2018 annual result came in at 162978.0, down 67.32% from the prior year.
- Liabilities from Discontinued Operations eased to 162978.0 in Q4 2018 per SIGY's latest filing, from 498635.0 in the prior quarter.
- Over five years, Liabilities from Discontinued Operations peaked at 498635.0 in Q4 2017 and troughed at 162978.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 162,978.00 |
| Dec 31, 2018 | 162,978.00 |
| Dec 31, 2017 | 498,635.00 |
| Dec 31, 2017 | 498,635.00 |